معرفی
Manu Shankar Hari is a triple-doctorate clinical academic (MB BS MD PhD[immunology] MSc[Epidemiology]) holding specialist fellowships in anaesthesia, intensive-care medicine and epidemiology (FRCA EDIC FFICM). His research fingerprint centres on COVID-19 immunopathology, post-COVID-19 syndromes, sepsis-related platelet biology and T-cell immunosenescence, evidenced by >350 citations and leadership of large UK consortium studies such as PHOSP-COVID and ISARIC4C.
Education & Qualifications:
- MB BS – primary medical degree
- MD – higher medical doctorate
- PhD in Immunology
- MSc in Epidemiology
- FRCA – Fellowship of the Royal College of Anaesthetists
- EDIC – European Diploma of Intensive Care Medicine
- FFICM – Fellowship of the Faculty of Intensive Care Medicine
Research Interests: Dr Hari’s work integrates bedside critical care with translational immunology. He interrogates how accelerated immune ageing shapes COVID-19 severity, delineates platelet–immune crosstalk in sepsis, and identifies determinants of recovery from post-COVID-19 dyspnoea using multicentre prospective cohorts and randomised trials.
Publication Trends: Recent first-author or senior-author papers in Immunity & Ageing, The Lancet Respiratory Medicine, The Lancet Regional Health – Europe, Shock and JAMA reveal a coherent programme spanning immunosenescence, antiplatelet therapy in COVID-19, and long-COVID respiratory sequelae.
Collaborations & Funding: He leads or co-leads national UK consortium grants (PHOSP-COVID, ISARIC4C) involving hundreds of investigators and institutions, supported by NIHR/MRC/UKRI funding streams, with extensive international collaboration networks.
